Cancer Chemotherapy and Pharmacology

, Volume 61, Issue 5, pp 791–802

Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid

  • Aiping Tong
  • Haiyuan Zhang
  • Zhengyu Li
  • Lantu Gou
  • Zhi Wang
  • Haiyan Wei
  • Minghai Tang
  • Shufang Liang
  • Lijuan Chen
  • Canhua Huang
  • Yuquan Wei
Original Article



Suberonylanilide hydroxamic acid (SAHA) is an orally administered histone deacetylase inhibitor (HDACI) that has shown significant antitumor activity in a variety of tumor cells. To evaluate if SAHA has an activity against liver cancer, and with an aim to identify the altered cellular factors upon SAHA treatment, human HepG2 cancer cell line was used as a model, and proteomic approach was utilized to elucidate the molecular mechanisms underlying SAHA’s antitumor activity.


Cell growth inhibition was measured by MTT method, and apoptosis was detected by means of flow cytometry analysis and TUNEL assay. Protein expression profiles were analyzed by 2-DE coupled with MALDI-Q-TOF MS/MS analysis.


A total of 55 differentially expressed proteins were visualized by 2-DE and Coomassie Brilliant Blue (CBB) staining. Of these, 34 proteins were identified via MS/MS analysis. Among the identified proteins, six proteins also displayed significant expression changes at earlier time points upon SAHA treatment, and such alterations were further confirmed by semi-quantitative RT-PCR. Together, at both the mRNA and protein levels, SAHA suppressed the expression of reticulocalbin 1 precursor (RCN1), annexin A3 (ANXA3) and heat shock 27 kDa protein 1 (HSP27), while increasing the expression of aldose reductase (AR), triosephosphate isomerase 1 (TPI) and manganese superoxide dismutase (SOD2).


SAHA remarkably inhibited proliferation of HepG2 cancer cells, and induced apoptosis in vitro. Using proteomics approaches, a variety of differentially expressed proteins were identified in HepG2 cancer cells before and after treatment with SAHA. This study will enable a better understanding of the molecular mechanisms underlying SAHA-mediated antitumor effects at the protein level.


Proteomics 2-DE HDACIs Suberonylanilide hydroxamic acid Hepatocellular carcinoma HepG2 



Suberonylanilide hydroxamic acid


Histone deacetylase


Histone deacetylase inhibitors


2-Dimensional polyacrylamide gel electrophoresis


Hepatocellular carcinoma


Reticulocalbin 1


Annexin A3


Heat shock 27 kDa protein 1


Aldose reductase


Triosephosphate isomerase 1


Manganese superoxide dismutase


  1. 1.
    Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA et al (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003–3007PubMedCrossRefGoogle Scholar
  2. 2.
    Narlikar GJ, Fan HY, Kingston RE (2002) Cooperation between complexes that regulate chromatin structure and transcription. Cell 108:475–487PubMedCrossRefGoogle Scholar
  3. 3.
    Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C et al (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165–5170PubMedGoogle Scholar
  4. 4.
    Cao ZA, Bass KE, Balasubramanian S, Liu L, Schultz B, Verner E et al (2006) CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Mol Cancer Ther 5:1693–1701PubMedCrossRefGoogle Scholar
  5. 5.
    Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA et al (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188–193PubMedCrossRefGoogle Scholar
  6. 6.
    Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202PubMedCrossRefGoogle Scholar
  7. 7.
    Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014–10019PubMedCrossRefGoogle Scholar
  8. 8.
    Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98:10833–10838PubMedCrossRefGoogle Scholar
  9. 9.
    Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C et al (2003) Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin: a (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278:12579–12589PubMedCrossRefGoogle Scholar
  10. 10.
    Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB (2006) Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281:5612–5622PubMedCrossRefGoogle Scholar
  11. 11.
    Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA (2006) Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 103:15540–15545PubMedCrossRefGoogle Scholar
  12. 12.
    El-Serag HB, Davila JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139:817–823PubMedGoogle Scholar
  13. 13.
    Wilson JF (2005) Liver cancer on the rise. Ann Intern Med 142:1029–1032PubMedGoogle Scholar
  14. 14.
    Cormier JN, Thomas KT, Chari RS, Pinson CW (2006) Management of hepatocellular carcinoma. J Gastrointest Surg 10:761–780PubMedCrossRefGoogle Scholar
  15. 15.
    Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG et al (2002) The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36:233–240PubMedCrossRefGoogle Scholar
  16. 16.
    Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S et al (2003) Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 103:572–576PubMedCrossRefGoogle Scholar
  17. 17.
    Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss Thomas S, Gottlicher M et al (2005) Apoptosis on hepatoma cells, but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 42:210–217PubMedCrossRefGoogle Scholar
  18. 18.
    Jain KK (2000) Applications of proteomics in oncology. Pharmacogenomics 1:385–393PubMedCrossRefGoogle Scholar
  19. 19.
    Kabuyama Y, Resing KA, Ahn NG (2004) Applying proteomics to signaling networks. Curr Opin Genet Dev 14:492–498PubMedCrossRefGoogle Scholar
  20. 20.
    Holly MK, Dear JW, Hu X, Schechter AN, Gladwin MT, Hewitt SM et al (2006) Biomarker and drug-target discovery using proteomics in a new rat model of sepsis-induced acute renal failure. Kidney Int 70:496–506PubMedGoogle Scholar
  21. 21.
    Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33:53–61PubMedCrossRefGoogle Scholar
  22. 22.
    Song H, Ethier SP, Dziubinski ML, Lin J (2004) Stat3 modulates heat shock 27 kDa protein expression in breast epithelial cells. Biochem Biophys Res Commun 314:143–150PubMedCrossRefGoogle Scholar
  23. 23.
    Neo JCH, Rose P, Ong CN, Chung MCM (2005) Beta-phenylethyl isothiocyanate mediated apoptosis: a proteomic investigation of early apoptotic protein changes. Proteomics 5:1075–1082PubMedCrossRefGoogle Scholar
  24. 24.
    Gray SG, Qian CN, Furge K, Guo X, Teh BT (2004) Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 24:773–795PubMedGoogle Scholar
  25. 25.
    Ozawa M, Muramatsu T (1993) Reticulocalbin, a novel endoplasmic reticulum resident Ca(2+)-binding protein with multiple EF-hand motifs and a carboxyl-terminal HDEL sequence. J Biol Chem 268:699–705PubMedGoogle Scholar
  26. 26.
    Tachikui H, Navet AF, Ozawa M (1997) Identification of the Ca(2+)-binding domains in reticulocalbin, an endoplasmic reticulum resident Ca(2+)-binding protein with multiple EF-hand motifs. J Biochem (Tokyo) 121:145–149Google Scholar
  27. 27.
    Kent J, Lee M, Schedl A, Boyle S, Fantes J, Powell M et al (1997) The reticulocalbin gene maps to the WAGR region in human and to the small eye Harwell deletion in mouse. Genomics 42:260–267PubMedCrossRefGoogle Scholar
  28. 28.
    Yu LR, Zeng R, Shao XX, Wang N, Xu YH, Xia QC (2000) Identification of differentially expressed proteins between human hepatoma and normal liver cell lines by two-dimensional electrophoresis and liquid chromatography-ion trap mass spectrometry. Electrophoresis 21:3058–3068PubMedCrossRefGoogle Scholar
  29. 29.
    Liu Z, Brattain MG, Appert H (1997) Differential display of reticulocalbin in the highly invasive cell line, MDA-MB-435, versus the poorly invasive cell line, MCF-7. Biochem Biophys Res Commun 231:283–289PubMedCrossRefGoogle Scholar
  30. 30.
    Gerke V, Moss SE (2002) Annexins: from structure to function. Physiol Rev 82:331–371PubMedGoogle Scholar
  31. 31.
    Hsiang CH, Tunoda T, Whang YE, Tyson DR, Ornstein DK (2006) The impact of altered annexin I protein levels on apoptosis and signal transduction pathways in prostate cancer cells. Prostate 66:1413–1424PubMedCrossRefGoogle Scholar
  32. 32.
    Niimi S, Harashima M, Gamou M, Hyuga M, Seki T, Ariga T et al (2005) Expression of annexin A3 in primary cultured parenchymal rat hepatocytes and inhibition of DNA synthesis by suppression of annexin A3 expression using RNA interference. Biol Pharm Bull 28:424–428PubMedCrossRefGoogle Scholar
  33. 33.
    Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10:86–103PubMedCrossRefGoogle Scholar
  34. 34.
    Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31:164–172PubMedCrossRefGoogle Scholar
  35. 35.
    Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP, Solary E (1999) HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J 13:2061–2070PubMedGoogle Scholar
  36. 36.
    Rane MJ, Pan Y, Singh S, Powell DW, Wu R, Cummins T et al (2003) Heat shock protein 27 controls apoptosis by regulating Akt activation. J Biol Chem 278:27828–27835PubMedCrossRefGoogle Scholar
  37. 37.
    Kammanadiminti SJ, Chadee K (2006) Suppression of NF-kappaB activation by Entamoeba histolytica in intestinal epithelial cells is mediated by heat shock protein 27. J Biol Chem 281:26112–26120PubMedCrossRefGoogle Scholar
  38. 38.
    Pacey S, Banerji U, Judson I, Workman P (2006) Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 172:331–358PubMedCrossRefGoogle Scholar
  39. 39.
    Guo Z, Boekhoudt GH, Boss JM (2003) Role of the intronic enhancer in tumor necrosis factor-mediated induction of manganous superoxide dismutase. J Biol Chem 278:23570–23578PubMedCrossRefGoogle Scholar
  40. 40.
    Church SL, Grant JW, Ridnour LA, Oberley LW, Swanson PE, Meltzer PS et al (1993) Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc Natl Acad Sci USA 90:3113–3117PubMedCrossRefGoogle Scholar
  41. 41.
    Weydert C, Roling B, Liu J, Hinkhouse MM, Ritchie JM, Oberley LW et al (2003) Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. Mol Cancer Ther 2:361–369PubMedGoogle Scholar
  42. 42.
    Venkataraman S, Jiang X, Weydert C, Zhang Y, Zhang HJ, Goswami PC et al (2005) Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells. Oncogene 24:77–89PubMedCrossRefGoogle Scholar
  43. 43.
    Weydert CJ, Waugh TA, Ritchie JM, Iyer KS, Smith JL, Li L et al (2006) Overexpression of manganese or copper-zinc superoxide dismutase inhibits breast cancer growth. Free Radic Biol Med 41:226–237PubMedCrossRefGoogle Scholar
  44. 44.
    Hodge DR, Xiao W, Peng B, Cherry JC, Munroe DJ, Farrar WL (2005) Enforced expression of superoxide dismutase 2/manganese superoxide dismutase disrupts autocrine interleukin-6 stimulation in human multiple myeloma cells and enhances dexamethasone-induced apoptosis. Cancer Res 65:6255–6263PubMedCrossRefGoogle Scholar
  45. 45.
    Yabe-Nishimura C (1998) Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 50:21–33PubMedGoogle Scholar
  46. 46.
    Hamaoka R, Fujii J, Miyagawa J, Takahashi M, Kishimoto M, Moriwaki M et al (1999) Overexpression of the aldose reductase gene induces apoptosis in pancreatic beta-cells by causing a redox imbalance. J Biochem (Tokyo) 126:41–47Google Scholar
  47. 47.
    Galvez AS, Ulloa JA, Chiong M, Criollo A, Eisner V, Barros LF et al (2003) Aldose reductase induced by hyperosmotic stress mediates cardiomyocyte apoptosis: differential effects of sorbitol and mannitol. J Biol Chem 278:38484–38494PubMedCrossRefGoogle Scholar
  48. 48.
    Ramana KV, Bhatnagar A, Srivastava SK (2004) Inhibition of aldose reductase attenuates TNF-alpha-induced expression of adhesion molecules in endothelial cells. FASEB J 18:1209–1218PubMedCrossRefGoogle Scholar
  49. 49.
    Murata M, Ohta N, Sakurai S, Alam S, Tsai J, Kador PF et al (2001) The role of aldose reductase in sugar cataract formation: aldose reductase plays a key role in lens epithelial cell death (apoptosis). Chem Biol Interact 130–132:617–625PubMedCrossRefGoogle Scholar
  50. 50.
    Miwa K, Nakamura J, Hamada Y, Naruse K, Nakashima E, Kato K et al (2003) The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res Clin Pract 60:1–9PubMedCrossRefGoogle Scholar
  51. 51.
    Gess B, Hofbauer KH, Deutzmann R, Kurtz A (2004) Hypoxia up-regulates triosephosphate isomerase expression via an HIF-dependent pathway. Pflugers Arch 448:175–180PubMedCrossRefGoogle Scholar
  52. 52.
    Jiang PZ, Gan M, Huang H, Shen XM, Wang S, Yao KT (2005) Proteomics-based identification of proteins with altered expression induced by 12-O-tetradecanoylphorbol 13-acetate in nasopharyngeal carcinoma CNE2 cells. Acta Biochim Biophys Sin (Shanghai) 37:97–106CrossRefGoogle Scholar
  53. 53.
    Lieu HY, Song HS, Yang SN, Kim JH, Kim HJ, Park YD et al (2006) Identification of proteins affected by iron in Saccharomyces cerevisiae using proteome analysis. J Microbiol Biotechnol 16:946–951Google Scholar
  54. 54.
    Richon VM (2006) Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor.95(Suppl 1):S2–S6Google Scholar
  55. 55.
    Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784PubMedCrossRefGoogle Scholar
  56. 56.
    Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51PubMedCrossRefGoogle Scholar
  57. 57.
    Lescuyer P, Hochstrasser DF, Sanchez JC (2004) Comprehensive proteome analysis by chromatographic protein prefractionation. Electrophoresis 25:1125–1135PubMedCrossRefGoogle Scholar
  58. 58.
    Corthals GL, Wasinger VC, Hochstrasser DF, Sanchez JC (2000) The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis 21:1104–1115PubMedCrossRefGoogle Scholar
  59. 59.
    Zhang CL, Richon V, Ni X, Talpur R, Duvic M (2005) Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125:1045–1052PubMedCrossRefGoogle Scholar
  60. 60.
    Huang C, Ida H, Ito K, Zhang H, Ito Y (2007) Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment. Biochem Pharmacol 73:990–1000PubMedCrossRefGoogle Scholar
  61. 61.
    Sonnemann J, Gange J, Pilz S, Stotzer C, Ohlinger R, Belau A et al (2006) Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 6:183PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Aiping Tong
    • 1
  • Haiyuan Zhang
    • 2
  • Zhengyu Li
    • 1
  • Lantu Gou
    • 1
  • Zhi Wang
    • 3
  • Haiyan Wei
    • 1
  • Minghai Tang
    • 1
  • Shufang Liang
    • 1
  • Lijuan Chen
    • 1
  • Canhua Huang
    • 1
  • Yuquan Wei
    • 1
  1. 1.The State Key Laboratory of Biotherapy, West China Hospital, and College of Life ScienceSichuan UniversityChengduPeople’s Republic of China
  2. 2.The School of MedicineYangtze UniversityShashiPeople’s Republic of China
  3. 3.Department of Oral Mucosal Diseases, West China Stomatological HospitalSichuan UniversityChengduPeople’s Republic of China

Personalised recommendations